EcoDrugPlus

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSSARG00000008570
Gene Symbol: ERBB4
1 External references
236 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSSARG00000004419
Gene Symbol: ESR1
1 External references
211 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSSARG00000004498
Gene Symbol: ESR2
3 External references
273 Possible Orthologues:

Estrogen Related Receptor Gamma

Ensembl ID : ENSSARG00000013825
Gene Symbol: ESRRG
1 External references
277 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSSARG00000010287
Gene Symbol: FDFT1
1 External references
215 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSSARG00000009660
Gene Symbol: FNTA
1 External references
216 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSSARG00000010181
Gene Symbol: FNTB
1 External references
210 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSSARG00000002501
Gene Symbol: FAP
1 External references
127 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSSARG00000000837
Gene Symbol: FLT1
1 External references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSSARG00000010421
Gene Symbol: FLT3
1 External references
133 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSSARG00000011306
Gene Symbol: FSHR
1 External references
199 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSSARG00000014421
Gene Symbol: FFAR2
1 External references
331 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).